The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRa, OSMRb, gp130, or the transcription factor STAT3. FR-specific induction of LIFRa occurs independently of de novo protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRa and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines.
Introduction
The members of the interleukin-6 (IL-6) subfamily of hematopoietic cytokines (henceforth termed 'IL-6 cytokines'), including IL-6, leukemia inhibitory factor (LIF) and oncostatin M (OSM), cooperate with the other inflammatory cytokines, including IL-1b, tumor necrosis factor a (TNFa), IL-12, interferon a and g (IFNa and g), and chemokines, in mediating the tissue reaction to trauma, infection, and tumor growth (Gadient and Patterson, 1999; Auernhammer and Melmed, 2000; Baumann and Gauldie, 1994; Wong and Wispe, 1997) . These cytokines are released at sites of injury by activated monocytes, neutrophils, mast cells, dentritic cells and lymphocytes (Gadient and Patterson, 1999; Auernhammer and Melmed, 2000; Grenier et al., 1999; Okamoto et al., 1997) . The factors act in paracrine fashion on adjacent endothelial, epithelial and stromal cells, which in turn secrete their own set of mediators. IL-6 cytokines play an important role not only in the local inflammatory process, but also in the systemic propagation of the acute phase reaction. IL-6 cytokines have also been implicated in early embryonic development, organogenesis, and differentiation, as well as tumor growth (Auernhammer and Melmed, 2000; Yoshida et al., 1996; Ware et al., 1995; Barash et al., 1999; Bajaj et al., 1993; Klausen et al., 2000; Nair et al., 1992) .
Each of the IL-6 cytokines is recognized by a specific receptor subunit: IL-6 by IL-6 receptor a (IL-6Ra), LIF by LIFRa, and OSM by gp130 or OSMRb (Auernhammer and Melmed, 2000; Mosley et al., 1996; Lindberg et al., 1998) . In combination with the shared signal-transducing gp130 subunit, they form high affinity, signaling-competent receptor complexes. The receptor-activated Janus protein tyrosine kinases (JAKs) phosphorylate tyrosine residues in the receptor cytoplasmic domain. These phosphorylated residues create docking sites for STAT transcription factors (STAT1, 3 and 5) and linker proteins, which propagate the signal to other pathways (ERK-1/2, JNK, PI3K) (Auernhammer and Melmed, 2000; Kim and Baumann, 1999; Heinrich et al., 1998) . Receptor signaling results downstream in activation of genes such as acute phase proteins (APPs), the cyclin-dependent kinase inhibitor p21 WAF1 (primarily through STATs) (Bellido et al., 1998; Kim and Baumann, 1999; Heinrich et al., 1998) , and immediate early response genes such as c-fos, c-jun and egr-1 (primarily through ERK1/2) (Kim and Baumann, 1999) . Ultimately, the profile of cytokinemediated changes in gene expression dictates changes in cell morphology, differentiation and generally suppresses proliferation.
The ability of a cell type to respond to IL-6 cytokines is determined by the expression pattern of the receptor subunit genes (Mosley et al., 1996; Douglas et al., 1997) . Every cell type in the adult organism expresses at least one of the receptors for IL-6 cytokines. However, the precise composition of active receptors that is expressed in a given cell type is determined firstly by the developmental differentiation program of the particular tissue cell and secondly by regulatory processes associated with a given receptor subunit (e.g., turnover; Blanchard et al., 2000) . However, the cell-specific pattern of receptor expression is often subject to profound alterations during malignant transformation. Changes can include a loss or gain in the expression of specific receptor subunit genes or modification of signaltransducing pathways that link to the IL-6 cytokine receptors. While the changes in receptor profiles occurring during tumorigenesis have inevitable consequences on the cytokine responsiveness of the cells, the specific alterations that may arise in a given tumor cell clone are not predictable. We hypothesize that the alterations in receptor composition contribute to the development of cancer cell phenotype characterized by proliferation that is less suppressed, if not enhanced by IL-6 cytokines. This regulatory phenotype is expected to be beneficial for tumor cells residing at sites of inflammation.
Altered receptor gene expression can arise from both genetic and epigenetic processes. The latter type, including DNA methylation and chromatin protein modification, i.e., histone acetylation, generally accounts for the increases and decreases of gene expression occurring during normal cell differentiation or oncogenesis (Jones and Laird, 1999; Ng and Bird, 1999; Nan et al., 1998; Weidle and Grossmann, 2000; Baylin and Herman, 2000; Rountree et al., 2001) . The study of Karpf et al. (1999) has provided the first evidence that the cytokine responsiveness of cancer cells is modulated by epigenetic process. Experimental demethylation by inhibition of DNA methyl transferase with 5-aza-2'-deoxycytidine (AZA) enhanced IFNa responsiveness (growth-inhibitory effect), primarily because of an increased expression of STAT1, 2 and 3, offering a new area of investigation on the combined use of AZA and IFNa for the treatment of IFNresistant tumors.
In this study we asked to what extent the process of histone acetylation contributes to the profile of responsiveness to IL-6 cytokines in normal and abnormal cell types. This is of particular importance considering that inhibitors for histone deacetylase (HDAC) are tested as anticancer drugs. The data show that the relatively low responsiveness to IL-6 cytokines of various untransformed cells as well as some carcinoma, leukemia or lymphoma cell lines, can be increased by treatment with the HDAC inhibitor FR901228 (FR). This drug effect is directly at the level of receptor gene transcription, depends in part on CBP/p300 coactivator, and correlates with the level of acetylated histone 3 associated with the receptor promoter region.
Results
The response profile to the IL-6 cytokines is cell type specific
The immediate activation of the JAK-STAT and ERK pathways by short-term treatment with IL-6 cytokines has been used to identify the presence and relative activity of specific receptor systems in various cell types (Gadient and Patterson, 1999; Klausen et al., 2000; Douglas et al., 1997; Blanchard et al., 2000; . Based on the cytokine-stimulated phosphorylation of STAT3, we determined that normal adult mouse hepatocytes respond equally to LIF, OSM and IL-6 (Figure 1a ). The level of phosphotyrosine STAT3 in OSM-stimulated liver cells was then used as reference for the quantitative comparison of the cytokine signaling in the various other cell types, (Figure 1b) . Normal, non-immortalized human bronchial and alveolar epithelial cells, like liver cells, have a strong response to OSM and IL-6, but only a barely detectable response to LIF. Fibroblasts from the same lung tissue show a strong OSM response, but a low reaction to both LIF and IL-6. In contrast, human lung macrophages, blood monocytes and T-cells, murine splenocytes and peritoneal macrophages have a strong response to IL-6, a low response to LIF and an undetectable response to OSM (Figure 1b , left side panels marked 'Control', and data not shown).
The activation of the ERK pathway relative to the STAT3 pathway, as judged by the immunodetectable level of phosphorylated ERK-1 and -2 versus STAT3, is much higher by OSM than by LIF or b) . This preference, which is detectable in many cell types, is attributed to the specific signaling capabilities of the OSMR complex (Klausen et al., 2000; Blanchard et al., 2000; Wang et al., 2000) . To obtain a reference for the maximal activation of the ERK pathway independent of IL-6 cytokine receptor signals, hepatocytes, fibroblasts and epithelial cells were treated with EGF and macrophages with lipopolysaccharides (LPS) (Figure 1a,b) . Only in splenocytes were we unable to achieve an appreciable activation of ERK-1 and -2 despite the fact that these cells did show the characteristic pattern of STAT recruitment by lymphocyte-reactive hematopoietic cytokines (e.g., IL-2 and -6; Figure 1b , bottom panel). The relative level of STAT and ERK activation in the various cell types by cytokines and growth factors was considered to reflect receptor activities and not a difference in expression levels of the signaling proteins since there was no significant difference in immunoreactive STAT3 and ERK-1/2 proteins in cell extract (Figure 1c) .
The cytokine response patterns established for the normal cells as shown in Figure 1 were then compared to the patterns of selected tumor lines of comparable histogenic origin (Table 1 , 'Control' column). The (Table 1 ) indicated major deviations from the cytokine profile of normal epithelial cells. These alterations are distinct from those found for hepatocarcinoma cells in that generally the OSM response is maintained high. An exception is the HCT8 cell line, which has a very low response to OSM and essentially none to LIF. The pattern of the monocytic and lymphocytic cell lines shows similarity with those of the primary cultures of macrophages and splenocytes in that IL-6 is the most effective of the IL-6 cytokines.
FR treatments increased the response to IL-6 cytokines
Inhibitors of DNA methyltransferase or HDAC have been shown to increase the cellular response to IFNs in cancer cell lines, suggesting an epigenetic control of cytokine responsiveness (Chen et al., 2000; Karpf et al., 1999) . To assess whether histone acetylation was also in part responsible for the specific differences in IL-6 cytokines responsiveness of both normal and abnormal cell types, we tested the effect of FR, a highly effective HDAC inhibitor, on normal cells (Figure 1b , right side panels) and different tumor cell lines (Table 1 , right side column). For an initial assessment, short-term primary cultures of normal fibroblasts, epithelial cells, macrophages or splenocytes were treated with FR for 24 h. The receptor action in the FR-treated cells was then probed by a 15 min challenge with cytokines. The immunodetectable STAT3 phosphorylation indicated an increased LIFR activity in each cell type. The increases ranged from twofold (in splenocytes) to as high as 10-fold (in fibroblasts and lung epithelial cells). FR treatment also enhanced two-and fivefold the OSM response in splenocytes and macrophages, respectively. In contrast, the OSM response appeared to be already maximal in epithelial cells and fibroblasts and, therefore, a further increase by FR treatment was not evident.
The responses to IL-6 and EGF in epithelial cells, EGF in fibroblasts, LPS in macrophages, and IL-2 in splenocytes were unchanged by FR (Figure 1b) . The IL-6 response was not modified even in cells that show a significant increase in the response to the other members of the IL-6 cytokine family, LIF and OSM. In fact the low IL-6 response of fibroblasts detectable at the level of ERK activation was reduced even further by FR treatment.
The influence of FR on the responsiveness to IL-6 cytokines, as seen in normal cells, could also be detected in transformed cell lines (Table 1 , right side columns). In each line, LIF response was either induced or enhanced. In those cells, which have a low to non-detectable OSM response, an increased OSM signaling was also identified. In contrast, the IL-6 response was either unaffected or even reduced. Exceptions proved to be MCF7 and C91PL cells that displayed a 10 -15-fold increase in IL-6 signaling toward STAT3 and ERK pathway. As shown below (Figure 4) , the mechanism for the enhanced cytokine signaling in the example of MCF7 cells is correlated with a broader spectrum of FR-increased signaling proteins than found in the other cell types.
Inhibition of histone deacetylation enhances transcriptional expression of IL-6 cytokine receptor subunit genes
In order to define the kinetics and time course of FR induced cytokine response independent of cell proliferation, we selected G 0 -arrested normal fibroblasts as experimental system. As shown in Figure 2a , FR treatment elicited within 1 h a high level of acetylated histone 3, that persists for at least 24 h. The appearance of acetylated histone 3 was followed within 2 h by an enhanced level of immunodetectable, fully processed LIFRa protein that reached a plateau after 6 -24 h. The change in LIFRa protein level was temporally correlated with an increased LIF-dependent activation of STAT3 (PY-STAT3, Figure 2a ) which was maximal after 24 h treatment. The immunodetectable levels for gp130 and STAT3 remained constant during the entire FR treatment. Serial dilution of FR established that maximal induction was attained at 200 nM ( Figure 2b , and data not shown), a concentration that was in agreement with the concentration observed to be optimal for lymphocytic cells (Byrd et al., 1999) . The action of FR on the expression of LIFRa is at the level of gene transcription and/or mRNA stabilization. A 3 -5-fold higher amount of LIFRa mRNA was measured after 6 h FR treatment. The induction appeared not to depend on prior protein synthesis of a mediator for it also occurred in cells with cycloheximide-inhibited protein synthesis (Figure 2c ). The expression of mRNA for OSMRb and gp130 in the same cells was not changed by FR. OSMRb mRNA was, however, elevated in cycloheximide-treated cells (Figure 2c ), suggesting a negative regulation of this mRNA by short-lived proteins.
The FR-enhanced expression and function of LIFRa were dependent on the continuous presence of FR. Upon removal of FR from the culture medium, the amount of acetylated histone 3, fully processed LIFRa protein, and the ability to activate STAT3 by LIF declined to pretreatment level within 48 h ( Figure 3 ). An essentially identical regulation of cytokine responses was obtained with trichostatin A (TSA), another HDAC inhibitor (data not shown).
Since FR at the dose of 200 nM and higher exerts a cytotoxic effect in proliferating cell cultures, including those used for the experiments listed in Table 1 , it was necessary to establish that the regulation of the IL-6 cytokine responses were not the consequence of a generic, drug-induced cellular stress reaction. To test this possibility, we applied various stress treatments, namely UVA (20J)-induced DNA damage, DNA alkylation by 100 nM adozelesin (Bhuyan et al., 1992) , hypoxia (24 h at 1% O 2 atmosphere), hyperthermia (culture at 40.58C for 12 h), treatment with 5 mM arsenic trioxide, or glucose depletion for 6 h. The expression of cytokine receptors and/or the cellular responsiveness to IL-6 cytokines did not increase as observed in FR-treated cells even though the standard stress markers, such Taken together, the results (Figures 1 -3 and Table  1 ) indicated that the response to LIF, OSM and, in few cases, to IL-6 could be specifically elevated by FR treatment in different cell types. The enhancement of the cell response to LIF was the most consistent effect. In assays with the various cell types that have not been described, we also found that FR treatment did not enhance other cytokine responses, such as IL-1b, IL-2, G-CSF, GM-CSF, EGF, basic FGF, or insulin.
FR treatment induces expression of IL-6 type receptor subunits and STAT3 in tumor cells
The studies of normal and many of the transformed cell types (Figures 1 -3 , Table 1 , and data not shown) indicate that FR has undetectable stimulatory activity on the expression of STAT3 and receptor subunits for IL-6 cytokines, with the exception of LIFRa. Since most of these cell types have already a robust expression of OSMRb, gp130, IL-6Ra and STAT3, a further enhancement of these by FR may not be Epigenetic control of IL-6 cytokine response F Blanchard et al detectable by the techniques used. However, we have also determined that several transformed cell lines have deviated from normal phenotypes by the reduced expression of components in the IL-6 cytokine receptors systems and these are sensitive to FR. Two prominent phenotypes are represented by MCF7 and HCT8 (Figure 4) .
In MCF7 cells, compared to all the cell types analysed, FR treatment not only elevated the level of LIFRa, but also that of gp130 and STAT3 (Figure 4a , center panel), two gene products that are expressed at low basal levels in MCF7 cells. OSMRb and ERK were expressed at high levels and these were not detectably affected by FR. The action of FR on gp130 and STAT3 may account in part for the more prominent effect of FR in elevating the response to all IL-6 cytokines, including IL-6 (Table 1 ). The broader action of FR on the expression of genes known to be sensitive to inhibition of histone deacetylation became evident when measuring the two tumor suppressors, gelsolin and p21 (Figure 4a ) (Chen et al., 2000; Mielnicki et al., 1999) .
HCT8 cells, like other tumor cell lines, enhance expression of LIFRa protein in response to FR treatment. The level attained is comparable to that of FR-treated normal fibroblasts (Figure 4a) . The same cells also demonstrated an induction of OSMRb starting from a level below immunodetection and a 3.5-fold increase of gp130. The expression of STAT3 and ERK1/2 was essentially unaffected. RT -PCR analysis confirmed the induction of mRNAs for both LIFRa and OSMRb in FR-as well as TSA-treated HCT8 cells (Figure 3b ). Only by analysing the products from lower PCR cycle numbers could we detect a twofold higher gp130 mRNA level in HDAC inhibitor-treated cells. Under the same RT -PCR assay conditions, the mRNA level for IL-6Ra and actin remained unchanged in control and drug-treated cells.
These examples of regulatory events in tumor cell lines (Table 1) , in particular the results with MCF7 and HCT8 cells (Figure 4) , support the notion that the FRenhanced responsiveness of these cells to IL-6 cytokines involves a transcriptional activation of the gene for LIFRa, and, in some cases also of the genes for gp130 and OSMRb. Armenante et al., 1999; Birger et al., 1999; Kang et al., 1999; Melki et al., 1999; Antequera et al., 1990; Baylin and Herman, 2000) . Moreover, direct associations between DNA methylation and chromatin structure have been established after the identification of several repressor complexes containing methyl-CpG binding proteins, chromatin remodeling factors, and histone deacetylases (Ng and Bird, 1999; Nan et al., 1998; Magdinier and Wolffe, 2001 ). Therefore, we investigated the methylation status of the LIFRa and gp130 promoter regions, and whether acetylated histones were associated with (Mosley et al., 1996) and the p16 gene (Magdinier and Wolffe, 2001 ) and on MCF7 and HCT8 cells, the two lines with a most distinct expression pattern for LIFRa and gp130 (Table 1 and Figure 4) . Two LIFRa promoters have been described (Wang and Melmed, 1997) . The first one has been shown to be active primarily in placental cells (placental promoter), whereas a second LIFRa promoter is active in other cell types (general promoter). The former promoter sequence was confirmed in our study, but we were unable to identify the general promoter by genomic PCR or to locate it in the CELERA or public databases. However, by 5' RACE using RNA derived from non-placental cells, Wang and Melmed (1997) have identified 28 bases representing the 3' end of the first exon of the general LIFRa mRNA. This sequence has been located in the middle of the first intron of the LIFRa gene (position +39 013 to 39 041 relative to the placental transcription start; Figure 5a ). A GC-rich region is detected around +38 000 and a potential transcription start for the general LIFRa mRNA is found at position +38 122 (Figure 5a,b) . Therefore, we used this region as representing the general LIFRa promoter in our analysis. The promoter of human gp130 has been characterized before (O'Brian and Manolagas, 1997) and the confirmed sequence was applied as probe (Figure 5a) . A methylation sensitive PCR assay that utilizes MspI (methylation insensitive) and HpaII (methylation sensitive) digestion of DNA followed by PCR amplification with primers that bridge the restriction site indicates that the general LIFRa and the gp130 promoters are non-methylated in HeLa cells (high LIFRa) and MCF7 cells (low LIFRa), whereas the placental LIFRa promoter (proximal GC rich region, Figure 5a ) appeared methylated ( Figure 6 ). Similar results were obtained with two other methylation sensitive enzymes, AvaI or SmaI (data not shown). Interestingly, in HCT8 cells, where LIFRa mRNA and protein were not detected (Figure 4a,b) , the placental and general LIFRa promoters were both methylated (Figure 5a) . Regardless of the level of expression, the gp130 promoter is not methylated in any of the three cell lines. In contrast, the p16 promoter is methylated in HCT8 and MCF7 cells but not in HeLa cells in agreement with the pattern of expression of this gene ( Figure 6 ).
These methylation analyses did not show an inverse correlation between receptor expression and promoter methylation status at the sites analysed, whereas p16 expression correlated with promoter hypomethylation as previously reported (Magdinier and Wolffe, 2001 ). We therefore investigated, by chromatin immunoprecipitation, the association of acetylated histone 3 with these promoter sequences (Figure 6b) . In HeLa cells, 
The activity of the gp130 and general LIFRa promoter is increased by FR treatment and involves CBP/p300
It has been previously demonstrated that transfected plasmids interact with histones to form nucleosomelike structures and that inhibition of HDAC can activate transcription (Xiao et al., 2000; Luo et al., 1998) . Therefore we inserted the 5'-flanking region of gp130 and LIFRa (both from the placental and general promoter) upstream of the CAT gene in pCAT ( Figure  5a ) and analysed their activities to direct enhanced transcription in FR-treated HeLa and MCF7 cells and in normal human lung fibroblasts (Figure 7a ). In comparison with basic pCAT vector, transcription from the gp130 and general LIFRa promoter was high in HeLa cells and was not further enhanced by FR treatment. The activities of the same gp130 and general LIFRa promoter were lower in fibroblasts and even more reduced in MCF7 cells. FR treatment increased the general LIFRa promoter activity twofold in fibroblasts and 15-fold in MCF7 cells. In the latter cells, the gp130 promoter activity was also 10-fold stimulated by FR. No appreciable activity was detected with the placental LIFRa promoter in any of the cell lines, even after FR treatment (Figure 7a ). The relative activities of the promoters in these three cell types in part reflected the expression of the endogenous gp130 and LIFRa genes.
A transcriptional complex containing SP1 transcription factor and the coactivator CBP/p300 participates in induction of promoters by TSA or other HDAC inhibitors through binding GC-boxes (Xiao et al., 2000; Vo and Goodman, 2001 ). The gp130 promoter studied here contains nine potential GC-boxes (SP1 binding sites; O'Brien and Manolagas, 1997) and the general LIFRa contains two (Figure 4b ). While overexpression of wild type SP1 in MCF7 cells was ineffective in modifying the activities of the receptor promoters (data not presented), transfection of an expression vector for wild type p300 produced a 2 -3-fold increase of the basal activity of the gp130 and LIFRa promoters (Figure 7b ). In the same cells, a minor further increase in the expression stimulated by FR was also detected. In contrast, when an expression vector for the dominant negative mutant of p300 (p300D; Avantaggiati et al., 1997) was introduced, the basal as well as the FR-induced activity was severalfold reduced (Figure 7b ). These data suggest that p300 participates in FR-induced transcription of both gp130 and LIFRa and that this action may involve cooperativity with SP1.
FR treatment sensitized MCF7 cells to the growth inhibitory effect of OSM
Collectively, the results presented thus far indicated that inhibitors of HDAC sensitize different cell lines to LIF and in some cases also to OSM and/or IL-6. In view of the proliferation-reducing activity of these cytokines, in particular of OSM and IL-6 (Figure 8 , normal epithelial cells) (Klausen et al., 2000; Kim and Baumann, 1999; Wang et al., 2000) , we predicted that FR treatment of IL-6 cytokine-resistant cells would introduce a growth inhibitory effect by these cytokines. This was indeed observed with MCF7 cells (Figure 8 ). OSM treatment did not decrease DNA synthesis in control MCF7 cells, however, in FR-treated cells the cytokine reduced thymidine incorporation by 65%. This increased responsiveness was observed despite the growth inhibition elicited by FR treatments alone (40%). Moreover, a strong potentiating effect was observed with the combination of FR and conditioned medium from LPS-activated lung macrophages, which are considered to be a biologically relevant source of inflammatory cytokines (Gadient and Patterson, 1999; Grenier et al., 1999; Okamoto et al., 1997; Cameron and Churchill, 1980) . In contrast, no significant influence of LIF or IL-6 on DNA synthesis was detected, attesting to the differences (1) in FRdependent increase of cellular responsiveness to IL-6 cytokines and (2) in the signaling among these IL-6 cytokines that determines growth inhibition (Klausen et al., 2000; Douglas et al., 1997; Wang et al., 2000) .
Discussion
In this study, we demonstrate that the expression profile of receptor subunits for IL-6 cytokines is cell type-specific and in part determined by regulatory mechanisms sensitive to modification of chromatin architecture independent of DNA replication. The data revealed that the responsiveness of various normal and transformed cell types to IL-6 cytokines is increased by treatments with drugs affecting histone acetylation. The expression of receptor subunits is elevated by HDAC inhibition by mechanisms that depend on CBP/p300 and target acetylated histones to receptor promoter regions. Epigenetic modifications of chromatin structure could explain the differentiated phenotype of normal cell types but also the aberrations in that phenotype emerging in transformed counterparts that include gain and loss of cytokine receptor expression. The ability to change the IL-6 type receptor expression by pharmacological intervention also provides a tool to alter the cellular response to the growth inhibitory activities of IL-6 cytokines. The suggestion for an epigenetic control of IL-6 cytokine receptors expression originated with the observation that the expression of LIFRa was clonally variable in the H-35 rat hepatocarcinoma cell line, as well as in a number of human lung cancer cells (Blanchard et al., in preparation) . Changes in DNA methylation was suggested as potential regulatory mechanism for altered LIF responsiveness. However, based on the recognition that DNA methylation and 3 H]thymidine incorporation was determined as described under Materials and methods. In each experimental group, the values for 3 H incorporation were expressed relative to the mean value of cultures not exposed to cytokines (defined as 100%). Bars indicate the values for standard deviation Epigenetic control of IL-6 cytokine responsehistone acetylation are often found to be functionally and mechanistically interrelated processes (Ng and Bird, 1999; Nan et al., 1998; Weidle and Grossmann, 2000; Magdinier and Wolffe, 2001) , we asked whether the enhancement of LIFRa expression could actually be achieved solely by elevating histone acetylation. Moreover, if histone acetylation alone is effective in modifying cellular responsiveness to IL-6 cytokine, then we predicted that interference with HDAC activity may have similar consequences in terminally differentiated cells, which are known to have developed low responsiveness to certain IL-6 cytokines. The present work demonstrated a regulatory role of HDAC activity on IL-6 cytokine receptor gene expression, in particular on LIFRa, not only in tumor cells but also in normal cells. The finding that cycloheximide treatment did not prevent FR-induction of LIFRa mRNA made it unlikely that the expression of receptor subunits was determined by epigenetic activation of an upstream regulator(s) of receptor expression, such as IL-6 (Armenante et al., 1999; Klouche et al., 1999; O'Brien and Manolagas, 1997) . Therefore, the hypothesis has emerged that the LIFRa gene, and probably the gp130 gene as well, is directly silenced by histone deacetylation of promoter DNA in cell-types with low expression of that gene.
In order to assess the potential mode of epigenetic control of receptor expression, we investigated possible correlations between histone acetylation at the LIFRa and gp130 promoters and expression of these genes. The regulation of these genes was compared to that of p16, a well-known acetylation-and methylationsensitive gene (Figure 6 ). Our limited analyses of methylation at the LIFRa and gp130 promoter sites and expression of the receptor genes failed to indicate a correlation and thus did not favor a causal relationship (Figure 6a ). In contrast, we observed that the high basal levels of gp130 and LIFRa expression, as found in HeLa cells, correlated with acetylated histone 3 associated with the receptor promoter region (Figures 3  and 6b) . Conversely, the low basal levels of gp130 and LIFRa, as found in MCF7, correlated with minimal association of acetylated histone 3 with promoter elements. Moreover, in cells where receptor levels were low, FR treatment efficiently enhanced the expression of the gp130 and LIFRa genes, concomitant with a rise in the level of acetylated histone 3 associated with the promoters. This suggests also that a methylationindependent transcriptional repressor complex is targeted to the promoters and, through recruitment of HDACs, participates in the regulation of these receptor genes. An example of such a repressor is Rb, which can inhibit transcription of cell cycle genes containing E2F sites through recruitment of a HDAC, and thereby promoting formation of nucleosomes (Luo et al., 1998) . Another possibility, based on IFNb and p21 WAF1 gene activation (Xiao et al., 2000; Vo and Goodman, 2001) , is that induction of receptor genes transcription by TSA or FR is mediated by the recruitment of a multi-protein transcriptional complex containing SP1 transcription factor and the coactivator CBP/p300, which possess intrinsic acetyltransferase activity. Our results with the gp130 and general LIFRa promoters strongly support the possibility that induction by FR required CBP/p300, presumably through interaction with SP1 family of transcription factors. Since both receptor subunit genes are also inducible by IL-6 cytokine treatment (Blanchard et al., 2001) , a cooperativity of STAT3 with SP1 and CBP/p300 may be effective (Giraud et al., 2002) . Further studies, especially for the LIFRa gene, are needed to identify more precisely these repressor and/or enhancer complexes, as well as their precise binding sites within receptor promoters.
Epigenetic modifications of chromatin structure are known to accompany every major cell function such as embryonic development, cell growth, differentiation, apoptosis, DNA repair and cell interactions (Weidle and Grossmann, 2000; Li et al., 1992 Li et al., , 1993 . With the exception of fibroblasts and several tumor cell lines in which HDAC inhibitors reduced the responsiveness to IL-6, epigenetic changes in the chromatin structure induced by TSA or FR raised the cellular response to IL-6 cytokines, and may therefore contribute to the expression pattern of LIFRa, gp130 and OSMRb in different cell types. Clearly, our study uncovered a regulatory activity for FR, a proposed anticancer drug (Weidle and Grossmann, 2000) , that was not restricted to tumor cells but was also observed in normal cells. Therefore, epigenetic modifications of chromatin structure could explain the differentiated phenotype of normal cell types but also aberration in that phenotype emerging in transformed counterparts.
Although drugs modifying chromatin structure have been attractive because of their preferential cytotoxic effects in transformed cells, warranting clinical trials (Weidle and Grossmann, 2000; Kantarjian et al., 1997; Momparler et al., 1997; Thibault et al., 1998) , the extent of effects on gene expression, cell differentiation, morphological changes and proliferation is not fully understood. For instance, HDAC inhibition induces gelsolin that in turn is implicated in actin filament reorganization and change in cell shape (Mielnicki et al., 1999; Hoshikawa et al., 1994) , whereas drugdependent inhibition of DNA synthesis and growth arrest in early G1 phase is dependent on induction of the cyclin-dependent kinase inhibitor p21 (Archer et al., 1998; Sandor et al., 2000) . The contribution of enhanced cytokine signaling to the phenotype of TSAor FR-treated cells is not known, but several studies have indicated that activated STAT1, STAT3 and/or STAT5 induce p21 gene transcription (Bellido et al., 1998; Chen et al., 2000; Shin et al., 2000; Karpf et al., 1999) and p27 accumulation (Klausen et al., 2000; Kortylewski et al., 1999) . These STAT isoforms are proposed to be critical mediators of growth inhibitory effects by IFNa/g and IL-6 type cytokines, particularly OSM. Conversely, activated ERK 1/2 is linked to sustained proliferation, and correlates with enhanced expression of immediate-early response genes such as cfos, c-jun and egr-1 (Kim and Baumann, 1999) . In our study, FR, probably as the result of an induced receptor and STAT3 expression/activation, introduces a sensitivity of the cytokine-resistant cell line MCF7 to growth inhibition by OSM (Figure 8 ). This potentiation is similar to that observed between these drugs and retinoic acid (Breitman and He, 1990) or IFNa/g (Chen et al., 2000; Karpf et al., 1999) .
Taken together, our results suggest a role for IL-6 cytokines, especially OSM, in FR-induced tumor growth arrest, as previously described for IFN-a/g (Chen et al., 2000; Karpf et al., 1999) . In vivo, drug treatments, through killing of tumor cells, generate a local inflammatory reaction (Gadient and Patterson, 1999; Auernhammer and Melmed, 2000; Baumann and Gauldie, 1994; Wong and Wispe, 1997) . The activated inflammatory cells deliver, in paracrine fashion, OSM, TNFa and IFNa/g to the surviving tumor cells (Grenier et al., 1999; Okamoto et al., 1997; Richards and Agro, 1994; Cameron and Churchill, 1980) . The combination of drug and inflammatory cytokines then acts as a more potent cytotoxic effector, which in turn could be exploited to improve efficacy of anticancer drug treatments.
Materials and methods

Tissue culture cells
All carcinoma cell lines (Table 1) were maintained in DMEM containing 10% FCS and antibiotics. THP1 monocytic leukemia and C91PL T lymphoma cell lines were maintained in RPMI containing 10% FCS. Primary cultures of human pulmonary fibroblasts and macrophages were prepared from residual lung tissues derived from surgical pneumectomy specimens and provided by the Tissue Procurement Service at Roswell Park Cancer Institute. All experimental work involving human tissue samples have been approved by the internal review board under protocol CIC00-17. Macrophages were mechanically extracted from lung tissues and plated (5610 5 per cm 2 ) into culture dishes. After 1 h, the adherent population was treated with 1 mg LPS per ml of RPMI containing 10% FCS. The conditioned medium was collected after incubation for 16 h. Fibroblasts growing out of macrophage-depleted lung tissue were passaged once and grown to confluency in six-well cluster plates in DMEM containing 10% FCS. Contact-dependent growth arrest was achieved by maintaining the confluent cultures for an additional 5 days in DMEM containing 2% FCS. Cultures of normal bronchial epithelial cells were established from tissue fragments collected by bronchial brushings during bronchioscopic examination of patients at Roswell Park Cancer Institute. The proliferating epithelial cells were maintained in serum-free keratinocyte medium supplemented with cholera toxin and EGF (GIBCO Life Sciences). Identity of the different cell types was confirmed by analysis of cytokeratin and integrin profile. Primary cultures of hepatocytes from C57BL/6J mice were prepared by in situ retrograde perfusion of the liver with collagenase. Splenocytes and 4 day thioglycollate-elicited mouse peritoneal macrophages were isolated and cultured with standard procedures.
Treatments of cells with HDAC inhibitors
Cell cultures were treated with various concentrations (maximal concentration 1 mM) of TSA or FR (NCI; NSC 630176) for 0 to 96 h. Standard treatment in most experiments involved 200 nM FR for 24 h.
Signaling analysis
Cells were incubated first for 2 -5 h in serum-free medium, and then treated for 15 min with 100 ng/ml recombinant human IL-6, LIF (Wyeth Research, Cambridge, MA, USA), OSM (Immunex Corp., Seattle, WA, USA), or EGF (Collaborative Research, Inc., San Jose, MO, USA). Cells were washed with PBS and immediately lysed in the culture wells or tubes for further analysis.
Immunoprecipitation and Western blotting
Cell monolayers were lysed in RIPA buffer (50 ml per cm 2 monolayers). Lysates were incubated with antibodies to LIFRa or gp130 (Santa Cruz Biotechnology) or OSMRb (Immunex Corp.), and protein-G-conjugated Sepharose (Amersham Pharmacia Biotechnology). The immunoprecipitates, or aliquots of whole cell lysates, were separated on 6% to 12% SDS-polyacrylamide gels and proteins transferred to protean membranes (Schleicher & Schuell). Wherever possible, replicates of sample series were electrophoresed on separate gels for identification of multiple antigens. To enable the quantitative comparison of the cytokine responsiveness among cell lines, each electrophoretic separation of cell extracts included an aliquot of OSM-treated mouse hepatocytes as internal reference. The membranes were reacted with antibodies to OSMRb (Immunex Corp.), LIFRa, gp130, STAT3, STAT5, ERK 1/2 (Santa Cruz Biotechnology), PY-STAT3, PY-STAT5, P-ERK (New England Biolabs, Inc.), p21 (Calbiochem, La Jolla, CA, USA), gelsolin (Sigma), acetylated histone 3 (Upstate Biotechnology, Lake Placid, NY, USA), and followed with secondary antibodies (ICN Biomedicals, Inc., Aurora, OH, USA) in PBS containing 0.1% TWEEN, 5% milk or 3% BSA. Immunoreactions were visualized by ECL according to the manufacturer (Amersham Pharmacia Biotech). Different time exposures (seconds to 30 min) of X-ray film to the luminescent patterns were made for optimal detection of quantitative signal differences. Digital densitometry of the patterns were analysed with the ImageQuant program (Molecular Dynamics). For comparison of immunoblot signals among different cell lines, the STAT3 and ERK1/2 signals of the co-analysed extract from OSM-treated mouse hepatocytes served as marker for the 100% level.
RT -PCR and Northern blot analysis
Cells were treated with the indicated drugs and total cellular RNA was extracted by the Trizol method (Life Technology, Grand Island, NY, USA). For RT -PCR analysis, aliquots of 5 mg of RNA were subjected to cDNA synthesis with 400 U of M-MLV reverse transcriptase (GIBCO/BRL) and 0.5 mg oligo(dT) 15-mer. The cDNA, present in 5 ml of this reaction mixture, was amplified with 0.625 U of Taq polymerase (Promega) and 10 pmol each of sense and antisense primers (Blanchard et al., 1998) . The thermal cycle profile was as follows: denaturation for 1 min at 948C, annealing for 45 s at 598C and extension for 1 min at 728C, for 35 cycles. For Northern blot analysis, aliquots of 20 mg of RNA were separated on 1.5% formaldehyde-agarose gel, transferred onto nylon membrane (Schleicher & Schuell) , and reacted with 32 P-labeled cDNA probes for human LIFRa, OSMRb or gp130. Ethidium bromide staining pattern of separated RNA was used as a marker for sample loading. The radioactive patterns were recorded by phosphorimaging (STORM, Molecular Dynamics) and analysed by the ImageQuant program.
Chromatin immunoprecipitation
Cell monolayers were washed and scraped in PBS, and proteins were cross-linked to DNA with 1% para-formaldehyde. Samples were solubilized in SDS buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1 with protease inhibitors) for 10 min on ice. Nucleoprotein complexes were sonicated to reduce DNA fragments to 500 -1000 base pairs. Debris were removed, the supernatant was diluted 1 : 10 in dilution buffer (0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 150 mM NaCl with protease inhibitors), and 5 ml of anti-acetylated histone 3 (residue 1 -21, Upstate Biotechnology) were added. Immune complexes were recovered by adding 40 ml of protein-G-conjugated Sepharose (Amersham Pharmacia Biotechnology). After washing, complexes were recovered in 1% SDS, 10 mM Tris pH 8.1, 1 mM EDTA, and cross-links were reversed by heating overnight at 658C. DNA was recovered by proteinase K digestion, phenol extraction, and ethanol precipitation.
